CPHI [CHINA PHARMAS,] DEF 14A: (Original Filing)
[SCHEDULE 14A INFORMATION þ o Check the appropriate box: o Preliminary Proxy Statement o þ Definitive Proxy Statement o Definitive Additional Materials o]
CPHI [CHINA PHARMAS,] DEF 14A: SCHEDULE 14A INFORMATION þ o Check the appropriate
[SCHEDULE 14A INFORMATION þ o Check the appropriate box: o Preliminary Proxy Statement o þ Definitive Proxy Statement o Definitive Additional Materials o]
BSPM [Biostar Pharmaceuticals,] 10-Q: (Original Filing)
[FORM 10-Q (Mark One) x September 30, 2010 For the quarterly period ended: Or ¨ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China 712046 (Zip code) 011-86-29-33686638 (Former name, former] [CERTIFICATION I, Ronghua Wang, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Deyin Chen, certify that: 1. I have reviewed this quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. EX-32.1 4 ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. EX-32.2 5 ex32-2.htm]
CPHI [CHINA PHARMAS,] DEFA14A: (Original Filing)
[SCHEDULE 14A INFORMATION o Check the appropriate box: o Preliminary Proxy Statement o 6(e)(2) ) o Definitive Proxy Statement Definitiveditional Materials o CHINA PHARMAS, Payment of Filing Fee (Check the appropriate box): No fee required. o Feemputed on table below per Exchange Act Rules14a-6(i)(1) and 0-11. (1)]
TPI [TIANYIN PHARMACEUTICAL] 10-Q: FORM 10-Q (Mark One) For the quarterly period
[FORM 10-Q (Mark One) For the quarterly period ended September 30, 2010 For the transition period from _______________ to _______________ Tianyin Pharmaceutical Co., Inc. Delaware (State or other jurisdiction of incorporation or organization) 23rd Floor, Unionsun Yangkuo Plaza No. 2, Block 3, Renmin Road South Chengdu, P. R. China, 610041 +0086-028-86154737 (Address, including zip code, and telephone number, Large Accelerated] [CERTIFICATION OF CHIEF EXECUTIVE OFFICER I, Guoqing Jiang certify that: 1. I have reviewed this quarterly report on Form 10-Q of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the] [CERTIFICATION OF CHIEF FINANCIAL OFFICER I, James Jiayuan Tong, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Tianyin Pharmaceutical Co., Inc. 2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2)T he information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Guoqing Jiang Chief Executive Officer & Chairman EX-32.1 4 ex32one.htm CERTIFICATION] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. James Jiayuan Tong Chief Financial Officer, Chief Accounting Officer, Chief Business and Development Officer, Director EX-32.2 5]
WX [WuXi PharmaTech (Cayman)] 6-K: (Original Filing)
[Form 6-K TABLE OF CONTENTS Page 3 4]
CPHI [CHINA PHARMAS,] DEF 14A: (Original Filing)
[SCHEDULE 14A INFORMATION o Check the appropriate box: o Preliminary Proxy Statement o Definitive Proxy Statement o Definitiveditional Materials o CHINA PHARMAS, Payment of Filing Fee (Check the appropriate box): o No fee required. o Feemputed on table below per Exchange Act Rules14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction]
TPI [TIANYIN PHARMACEUTICAL] SC 13D/A: (Original Filing)
[FORM OF RULE 10B5-1 TRADING PLAN October 11, 2010 This Trading Plan (the “Trading Plan”) is entered into on Time Poly Management Limited Tianyin Pharmaceutical Co., Inc. TPI between Seller and UBSFS agree as follows: 1. Specific Plan of Sale 2. Fees/Commissions 0.05 3. (a) (b) All investment decisions on behalf of Seller, including without limitation, decisions to purchase or] [(Amendment No. 3) TIANYIN PHARMACEUTICAL CO., INC. (Name of Issuer) SCHEDULE 13D/A Common Stock, $.001 par value (Title of Class of Securities) 88630M104 (CUSIP Number) Time Poly Management Ltd. Unit 06, 21/F, Beautiful Group Tower, 77 Connaught Road, Central, Hong Kong Telephone: (852) 3583 3340; Fax: (852) 3585 6021 (Name, Address and Telephone Number of Person Authorized to Receive Notices]
WX [WuXi PharmaTech (Cayman)] 6-K: Form 6-K TABLE OF CONTENTS Page 3 4
[Form 6-K TABLE OF CONTENTS Page 3 4]
CPHI [CHINA PHARMAS,] DEF 14A: SCHEDULE 14A INFORMATION o Check the appropriate box:
[SCHEDULE 14A INFORMATION o Check the appropriate box: o Preliminary Proxy Statement o Definitive Proxy Statement o Definitiveditional Materials o CHINA PHARMAS, Payment of Filing Fee (Check the appropriate box): o No fee required. o Feemputed on table below per Exchange Act Rules14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction]
